Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer
| Autor: | Aya Miyagawa-Hayashino, Masayoshi Inoue, Yuta Sonobe, Takahiro Yamada, Tadaaki Yamada, Satoru Okada, Masahiro Iwasaku, Koichi Takayama, Yusuke Chihara, Eiichi Konishi, Tatsuya Imabayashi, Takayuki Shimamoto, Yoshiko Kaneko, Akihiro Yoshimura, Junji Uchino |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Enolase Clone (cell biology) B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine Antineoplastic Agents Immunological Internal medicine medicine Biomarkers Tumor Humans Lung cancer Aged Retrospective Studies Aged 80 and over Chemotherapy biology business.industry Antibodies Monoclonal Retrospective cohort study Middle Aged medicine.disease Prognosis Small Cell Lung Carcinoma respiratory tract diseases Survival Rate 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Immunohistochemistry Female Non small cell Antibody business Follow-Up Studies |
| Zdroj: | Lung cancer (Amsterdam, Netherlands). 137 |
| ISSN: | 1872-8332 |
| Popis: | Objective Small cell lung cancer (SCLC), which accounts for approximately 15% of all lung cancer cases, has high initial sensitivity to chemotherapy. However, clinical outcomes have not improved in the past two decades. Therefore, novel biomarkers are needed to prolong survival in patients with advanced SCLC. Material and methods In this retrospective study, we assessed 44 patients with SCLC who underwent first-line or adjuvant chemotherapy. We analyzed PD-L1 expression in SCLC tumors using three specific anti-PD-L1 antibody clones (28-8, 22C3, and SP263) and assessed their correlation with clinical profiles. Results Each clone yielded PD-L1 positivity as follows: 10 cases with 28-8, eight cases with 22C3, and six cases with SP263. Eleven patients tested positive with at least one of the three anti-PD-L1 antibodies, and 33 patients tested negative with all anti-PD-L1 antibodies. Serum neuron-specific enolase levels at diagnosis were significantly higher in negative tumors than in positive tumors with the 28-8 clone (p = 0.036) and, similarly, tended to be higher in negative tumors with the 22C3 and SP263 clones. Conclusion These observations suggest that PD-L1 is detected in SCLC tumors at a similar rate and with similar clinical correlates when detected using any of these three anti-PD-L1 clones. Further large-scale investigations are warranted to reveal the roles of PD-L1 expression in patients with SCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect